Deaner JD, Srivastava SK, Hajj-Ali RA, et al. - In this retrospective case series involving 17 patients, researchers sought to explain the frequency of ocular flares in patients with non-infectious uveitis who switch from originator infliximab to biosimilar infliximab. All patients with non-infectious uveitis who were switched from originator infliximab to biosimilar infliximab-abda for non-medical reasons have been reviewed. Excluded were patients if they had less than three months of follow-up on either drug. Patients who switch to biosimilar infliximab-abda report more flares than previously treated with originator infliximab. Patients who switch to biosimilar infliximab should be closely monitored by providers, particularly within the first 90 days. Upon switching, those who do flare will achieve quiescence with increased biosimilar dosing.